Hodgkin

Lymphoma Research Foundation to Honor Esteemed Lymphoma Physician Kara Kelly, MD at Annual Gala on September 28

Retrieved on: 
Wednesday, August 2, 2023

NEW YORK, Aug. 2, 2023 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF), the nation's largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services, will host its 2023 Annual Gala on Thursday, September 28, at the Ziegfeld Ballroom in New York City.

Key Points: 
  • Genmab will be presented with the Lymphoma Research Foundation's Corporate Leadership Award for excellence in development of differentiated antibody therapeutics.
  • Honored at this year's gala will be LRF Scientific Advisory Board (SAB) member Kara Kelly, MD, who will recieve LRF's Distinguished Leadership Award.
  • "I am so incredibly honored to be receiving the Distinguished Leadership Award from the Lymphoma Research Foundation.'
  • We are proud to support the important work of the Lymphoma Research Foundation in achieving our shared goals for patients."

Hodgkin's Lymphoma Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The publisher estimates that in 2019, there were 80,800 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
  • In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin's lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
  • Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin's lymphoma, followed by Bristol Myers Squibb.

Global Hodgkin Lymphoma Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021

b'The "Global Hodgkin Lymphoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hodgkin Lymphoma Epidemiology and Patient Flow Analysis - 2021, provides Hodgkin Lymphoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Hodgkin Lymphoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hodgkin Lymphoma Epidemiology and Patient Flow Analysis - 2021, provides Hodgkin Lymphoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Hodgkin Lymphoma patients, history of the disease at the population level (Hodgkin Lymphoma prevalence, Hodgkin Lymphoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Hodgkin Lymphoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Hodgkin Lymphoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Hodgkin Lymphoma patients segments through age groups, gender, and disease sub-types\nEvaluate Hodgkin Lymphoma market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005205/en/\n'

Global Non-Hodgkin Lymphoma Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021

b'The "Global Non-Hodgkin Lymphoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Hodgkin Lymphoma Epidemiology and Patient Flow Analysis - 2021, provides Non-Hodgkin Lymphoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Non-Hodgkin Lymphoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Hodgkin Lymphoma Epidemiology and Patient Flow Analysis - 2021, provides Non-Hodgkin Lymphoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Non-Hodgkin Lymphoma patients, history of the disease at the population level (Non-Hodgkin Lymphoma prevalence, Non-Hodgkin Lymphoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Non-Hodgkin Lymphoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Non-Hodgkin Lymphoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Non-Hodgkin Lymphoma patients segments through age groups, gender, and disease sub-types\nEvaluate Non-Hodgkin Lymphoma market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005845/en/\n'

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

Retrieved on: 
Wednesday, April 14, 2021

b'Veracyte (Nasdaq: VCYT) today announced a key milestone in its companion diagnostics program with Acerta Pharma, the hematology research and development arm of AstraZeneca (LSE/STO/NYSE: AZN).

Key Points: 
  • b'Veracyte (Nasdaq: VCYT) today announced a key milestone in its companion diagnostics program with Acerta Pharma, the hematology research and development arm of AstraZeneca (LSE/STO/NYSE: AZN).
  • The LymphMark test uses gene-expression profiling of RNA extracted from surgical tissue to classify the \xe2\x80\x9ccell of origin\xe2\x80\x9d subtype of DLBCL tumors.
  • With Veracyte\xe2\x80\x99s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
  • 2016;127(20):2375-2390.\nii Miranda-Filho A, Pi\xc3\xb1eros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma.

United States Hodgkin Lymphoma Market and Competitive Landscape 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021

The "US Hodgkin Lymphoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Hodgkin Lymphoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Hodgkin Lymphoma Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Hodgkin Lymphoma pipeline products, Hodgkin Lymphoma epidemiology, Hodgkin Lymphoma market valuations and forecast, Hodgkin Lymphoma drugs sales and competitive landscape in the US.
  • Hodgkin Lymphoma pipeline: Find out the products in clinical trials for the treatment of Hodgkin Lymphoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Hodgkin Lymphoma drugs: Identify key products marketed and prescribed for Hodgkin Lymphoma in the US, including trade name, molecule name, and company
    Hodgkin Lymphoma market valuations: Find out the market size for Hodgkin Lymphoma drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Hodgkin Lymphoma drugs market share: Find out the market shares for key Hodgkin Lymphoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Hodgkin Lymphoma products

United States Non-Hodgkin Lymphoma Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 11, 2021

The "US Non-Hodgkin Lymphoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Non-Hodgkin Lymphoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Non-Hodgkin Lymphoma Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Non-Hodgkin Lymphoma pipeline products, Non-Hodgkin Lymphoma epidemiology, Non-Hodgkin Lymphoma market valuations and forecast, Non-Hodgkin Lymphoma drugs sales and competitive landscape in the US.
  • Non-Hodgkin Lymphoma pipeline: Find out the products in clinical trials for the treatment of Non-Hodgkin Lymphoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Non-Hodgkin Lymphoma drugs: Identify key products marketed and prescribed for Non-Hodgkin Lymphoma in the US, including trade name, molecule name, and company
    Non-Hodgkin Lymphoma market valuations: Find out the market size for Non-Hodgkin Lymphoma drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Non-Hodgkin Lymphoma drugs market share: Find out the market shares for key Non-Hodgkin Lymphoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Non-Hodgkin Lymphoma products

DGAP-News: EVOTEC EXPANDS OXFORDSHIRE SITE INTO A FULLY-INTEGRATED R&D CENTRE NAMED 'DOROTHY CROWFOOT HODGKIN CAMPUS'

Retrieved on: 
Thursday, November 12, 2020

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the expansion of the Company's existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the expansion of the Company's existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus.
  • The location also facilitates excellent partnership opportunities in the Oxford and UK-wide academic and biotech scene.
  • Having heard Bernal lecture on metals in Oxford, Dorothy Crowfoot went to Cambridge to work with J.D.
  • In 1946, Dorothy Crowfoot Hodgkin took part in the meetings which led to the foundation of the International Union of Crystallography.

Global Non-Hodgkin Lymphoma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 15, 2020

The "Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Non-Hodgkin Lymphoma Market and Competitive Landscape - 2020, provides comprehensive insights into the Non-Hodgkin Lymphoma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Non-Hodgkin Lymphoma market size and drug sales.
  • Non-Hodgkin Lymphoma pipeline: Find out drugs in clinical trials for the treatment of Non-Hodgkin Lymphoma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Non-Hodgkin Lymphoma drugs: Identify key drugs marketed and prescribed for Non-Hodgkin Lymphoma in the US, including trade name, molecule name, and company
    Non-Hodgkin Lymphoma market valuations: Find out the market size for Non-Hodgkin Lymphoma drugs in 2019 by countries.

Global Hodgkin's Lymphoma Market: Opportunity Analysis and Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020

The "Hodgkin's Lymphoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hodgkin's Lymphoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Given the high cure rate for this indication, these two early setting are the most determinant of global sales for Hodgkin's lymphoma.
  • Topline Hodgkin's lymphoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Analysis of the current and future market competition in the global Hodgkin's lymphoma therapeutics market.